FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20

Washington, D.C. 20549	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
OTT LINE IT OF OTT ATOES IN BEITE FOR A CONTRECT IN	Estimated average burden			

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RIGGS RORY B					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]										k all app	ionship of Reporti all applicable) Director		son(s) to Is	
(Last)	(Fir	st) (N	/liddle)	-	3. Date of Earliest Transaction (Month/Day/Year) 09/30/2023										Office below	er (give title v)		Other (s below)	specify
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) NEW Y	reet) EW YORK NY 10016												Form filed by More than One Reporting Person					orting	
(Oit)						Rule 10b5-1(c) Transaction Indication													
(City)	(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of,	or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				y/Year) Execution			tion Date, Trans		ction Instr.	4. Securities Disposed O 5)	s Acquired (A) or f (D) (Instr. 3, 4 ar		nd Securit Benefic		ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o (D)	Price		Transa	orted isaction(s) tr. 3 and 4)			(Instr. 4)
Common Stock 09/30/2					2023			A		345	A	\$52	52.09		78,984		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rities iired r osed) : 3, 4	Expiration Day/\(\text{Month/Day/\)\(\text{S}\)		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)				9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Ownership	Beneficial Ownership tt (Instr. 4)		
					Code	v	(A) (D)		Date Exercisable		Expiration Date	Number of Title Shares							

Explanation of Responses:

Remarks:

/s/ Lawrence J. Hineline, 10/02/2023 Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.